Board of Directors

Topelia has in place a highly experienced group of professionals whose technical and managerial backgrounds are outlined below:

Prof Thomas Borody 

Founder, Medical Director

Prof Borody is most famous for his ground-breaking work developing the triple therapy cure for peptic ulcers in 19871, which has saved hundreds of thousands of lives, and the Australian health system more than $10 billion in medical care and operations2. Professor Borody has more than 190 patents and applications, 3 FDA-approved drugs on the market, and more than 300 peer-reviewed papers published.

Read more

Dr David Fox 

MD and CEO

Dr David Fox has enjoyed guiding and growing biotech companies as a fund manager, management consultant, tech transfer officer, equities analyst and personal investor for almost 20 years at groups including MTPConnect, Shaw and Partners, and Oracle Investment Management. David gained experience on the buy and sell-side of the financial markets after gaining first class honours with majors in microbiology and pharmacology followed by a PhD in finance.

Read more

Mr Paul Negus 

Non-executive Director

Paul brings over 30 years’ experience, providing corporate and taxation advice across a range of industries. Paul was a Director at PriceWaterhouseCoopers and more recently is a Director of his own consultancy practice, GSPN Pty Ltd. Paul’s areas of advice concentrate on issue resolution (including disputes) and consideration of value add opportunities.

Read more

Dr Julie Simmons 

Non-executive Director

Dr Julie Simmons has over 22 years’ professional experience as a veterinarian and experienced business owner, with a comprehensive background in medical device innovation, clinical practice, legal and regulatory affairs. Having co-founded, led and overseen the strategic growth and sale of a medical device company over 17 years, and as a graduate of the Australian Institute of Company Directors, Dr Simmons brings experience-based insight to the Topelia board for effective and ongoing governance and management.

Read more

References

1  Borody, T.J. (2016).  Development of novel therapies for gut dysbioses. Open Publications of UTS Scholars (OPUS). Identifier: http://hdl.handle.net/10453/52985 Link to thesis: https://opus.lib.uts.edu.au/bitstream/10453/52985/6/01front.pdf  2  Eslick, G.D., Tilden, D., Arora, N., Torres, M. & Clancy, R.L. (2020). Clinical and economic impact of “triple therapy” for Helicobacter pylori eradication on peptic ulcer disease in Australia. Helicobacter, 25(6).  Doi: 10.1111/hel.12751 Link to article: https://onlinelibrary.wiley.com/doi/epdf/10.1111/hel.12751